| 货号 | HB132016 |
|---|---|
| 品牌 | abinScience |
| 种属反应性 | Human |
| 应用 | Research Grade Biosimilar |
| 宿主 | Mouse |
| 同种型 | IgG2a, kappa |
| 表达系统 | Mammalian Cells |
| 克隆类型 | Monoclonal |
| 靶标 | Alpha-(1,3)-fucosyltransferase 4, ELAM-1 ligand fucosyltransferase, Fucosyltransferase 4, Fucosyltransferase IV, Galactoside 3-L-fucosyltransferase, Fuc-TIV, FCT3A, FUT4, ELFT, FucT-IV |
| 内毒素水平 | Please contact the lab for this information. |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G, purified from cell culture supernatant. |
| Accession号 | P22083 |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS,pH7.4. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 别名 | Fanolesomab |
| 背景 | Technetium (99mTc) fanolesomab (trade name NeutroSpec, manufactured by Palatin Technologies) is a mouse monoclonal antibody formerly used to aid in the diagnosis of appendicitis. It is labeled with a radioisotope, technetium-99m (99mTc). History and use NeutroSpec was approved by the U.S. Food and Drug Administration (FDA) in June 2004 for imaging of patients with symptoms of appendicitis. It consisted of an intact murine (mouse) IgM monoclonal antibody against human CD15, labeled with technetium-99m so as to be visible on a gamma camera image. Since anti-CD15 antibodies bind selectively to white blood cells such as neutrophils, it could be used to localize the site of an infection. Deaths and associated recall The FDA received reports from Palatin of 2 deaths and 15 life-threatening adverse events in patients who had received NeutroSpec. These events occurred within minutes of administration of NeutroSpec and included shortness of breath, low blood pressure, and cardiopulmonary arrest. Affected patients required resuscitation with intravenous fluids, blood pressure support, and oxygen. Most, but not all, of the patients who experienced these events had existing cardiac and/or pulmonary conditions that may have placed them at higher risk for these adverse events. A review of all post-marketing reports showed an additional 46 patients who experienced adverse events that were similar but less severe. All of the reactions occurred immediately after NeutroSpec was administered. Marketing of the product was suspended in December 2005. References Further reading External links Technetium (99mTc) Fanolesomab from Micromedex |
| Note | For research use only. Not for use in clinical or therapeutic applications. |
SEC-HPLC detection for Research Grade Fanolesomab.
027-87433958/17302791434
武汉东湖新技术开发区神墩四路666号研发楼B区3层东
